Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Radhamani Kannaiyan & Daruka Mahadevan. (2018) A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Review of Anticancer Therapy 18:12, pages 1249-1270.
Read now
Read now
Vivek Narayan & Naomi Balzer Haas. (2016) Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives. International Journal of Nephrology and Renovascular Disease 9, pages 65-72.
Read now
Read now
Mustafa Erman, Mustafa Benekli, Mert Basaran, Sevil Bavbek, Suleyman Buyukberber, Ugur Coskun, Gokhan Demir, Bulent Karabulut, Berna Oksuzoglu, Metin Ozkan, Alper Sevinc & Suayib Yalcin. (2016) Renal cell cancer: overview of the current therapeutic landscape. Expert Review of Anticancer Therapy 16:9, pages 955-968.
Read now
Read now
Sergio Bracarda, Daniel Castellano, Giuseppe Procopio, Juan M Sepúlveda, Michele Sisani, Elena Verzoni & Manuela Schmidinger. (2014)
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. Expert Opinion on Drug Safety 13:4, pages 497-510.
Read now
Read now
Han Hsi Wong & Tim Eisen. (2013) Tivozanib for the treatment of metastatic renal cancer. Expert Review of Anticancer Therapy 13:6, pages 649-660.
Read now
Read now
Tor-Christian Aase Johannessen, Marek Wagner, Oddbjorn Straume, Rolf Bjerkvig & Hans Petter Eikesdal. (2013) Tumor vasculature: the Achilles' heel of cancer?. Expert Opinion on Therapeutic Targets 17:1, pages 7-20.
Read now
Read now
Articles from other publishers (49)
Manmeet Kaur, Mandeep Kaur, Tania Bandopadhyay, Aditi Sharma, Anu Priya, Arvind Singh & Bubun Banerjee. (2023) Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs. Physical Sciences Reviews 8:10, pages 3393-3446.
Crossref
Crossref
Qian Zhong, Xina Xiao, Yijie Qiu, Zhiqiang Xu, Chunyu Chen, Baochen Chong, Xinjun Zhao, Shan Hai, Shuangqing Li, Zhenmei An & Lunzhi Dai. (2023) Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. MedComm 4:3.
Crossref
Crossref
Indu Passi, Koushal Billowria, Bhupinder Kumar & Pooja A. Chawla. (2023) Tivozanib: A New Hope for Treating Renal Cell Carcinoma. Anti-Cancer Agents in Medicinal Chemistry 23:5, pages 562-570.
Crossref
Crossref
Sang Joon Shin, Jae Lyun Lee, Tae Gyun Kwon, Byoung Young Shim, Ho Seok Chung, Sang-Hee Kim & Se Hoon Park. (2022) Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy. Cancer Research and Treatment.
Crossref
Crossref
Hamidreza Zalpoor, Fatemeh Aziziyan, Mahsa Liaghat, Maryam Bakhtiyari, Abdullatif Akbari, Mohsen Nabi-Afjadi, Razieh Forghaniesfidvajani & Nima Rezaei. (2022) The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors. Cell Communication and Signaling 20:1.
Crossref
Crossref
Claude M. Grigg, Earle F. Burgess, Stephen B. Riggs, Jason Zhu & Derek Raghavan. 2017. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
10
.
Ruslan A. Zukov, Denis V. Chernyaev & Alexandra R. Zulkaidarova. (2022) Combination therapy regimens in the treatment of metastatic renal cell carcinoma: A review. Journal of Modern Oncology 24:2, pages 191-198.
Crossref
Crossref
Vanessa Königs, Sandra Pierre, Martin Schicht, Jessica Welss, Lisa Hahnefeld, Vittoria Rimola, Elke Lütjen-Drecoll, Gerd Geisslinger & Klaus Scholich. (2022) GPR40 Activation Abolishes Diabetes-Induced Painful Neuropathy by Suppressing VEGF-A Expression. Diabetes 71:4, pages 774-787.
Crossref
Crossref
Aleksandra Sochacka-Ćwikła, Marcin Mączyński & Andrzej Regiec. (2022) FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. Molecules 27:7, pages 2259.
Crossref
Crossref
Sangmin Jung, Hyeonsu Jo, Sujin Hyung & Noo Li Jeon. 2022. Microfluidics and Biosensors in Cancer Research. Microfluidics and Biosensors in Cancer Research
231
256
.
Sahar M. Abou-Seri, Amal A.M. Eissa, Mohamed G.M. Behery & Farghaly A. Omar. (2021) Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2. Bioorganic Chemistry 116, pages 105334.
Crossref
Crossref
Aini Hyytiäinen, Wafa Wahbi, Otto Väyrynen, Kauko Saarilahti, Peeter Karihtala, Tuula Salo & Ahmed Al-Samadi. (2021) Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?. Frontiers in Oncology 11.
Crossref
Crossref
Ozgur Tanriverdi, Sedef Ates, Kerim K Sandal, Selcuk Uylas, Islam C Bosna & Ali Alkan. (2020) Left ventricular dysfunction associated with axitinib and nivolumab experience in an advanced renal cell carcinoma. Journal of Oncology Pharmacy Practice 26:7, pages 1765-1768.
Crossref
Crossref
Qiuju Xun, Zhen Wang, Xianglong Hu, Ke Ding & Xiaoyun Lu. (2020) Small-Molecule CSF1R Inhibitors as Anticancer Agents. Current Medicinal Chemistry 27:23, pages 3944-3966.
Crossref
Crossref
Huantian Zhao, Jiefang Huang, Jing Zhang, Yu Tang & Yuanming Zhang. (2020)
Synthesis of 1
H
‐Indazoles and Quinazolines Using Additive Intermediates of Grignard Reagents to 2‐Amino Benzonitriles
. ChemistrySelect 5:10, pages 3007-3010.
Crossref
Crossref
Michio Kimura, Eiseki Usami, Hitomi Teramachi & Tomoaki Yoshimura. (2020) A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma. Molecular and Clinical Oncology.
Crossref
Crossref
Yoshifumi Kadono, Hiroyuki Konaka, Kouji Izumi, Satoshi Anai, Kiyohide Fujimoto, Kei Ishibashi, Noriyasu Kawai, Taku Kato, Akinori Iba, Naoya Masumori, Kenichi Yoshimura & Atsushiu Mizokami. (2019) Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study. Contemporary Clinical Trials Communications 15, pages 100403.
Crossref
Crossref
Tomoaki Takai, Takuya Tsujino, Yuki Yoshikawa, Teruo Inamoto, Nobuhiko Sugito, Yuki Kuranaga, Kazuki Heishima, Tomoyoshi Soga, Kotaro Hayashi, Kanjiro Miyata, Kazunori Kataoka, Haruhito Azuma & Yukihiro Akao. (2019) Synthetic miR-143 Exhibited an Anti-Cancer Effect via the Downregulation of K-RAS Networks of Renal Cell Cancer Cells In Vitro and In Vivo. Molecular Therapy 27:5, pages 1017-1027.
Crossref
Crossref
Manni Wang, Yu Liu, Yuan Cheng, Yuquan Wei & Xiawei Wei. (2019) Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1871:2, pages 199-224.
Crossref
Crossref
Haipeng Huang, Yunhong Wu, Weijin Fu, Xiaoming Wang, Liquan Zhou, Xiaolong Xu, Fu Huang & Yi Wu. (2019) Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression. International Journal of Molecular Medicine.
Crossref
Crossref
B. Ya. Alekseev, I. M. Shevchuk & A. D. Kaprin. (2018) Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma. Cancer Urology 14:2, pages 68-78.
Crossref
Crossref
Ondřej Fiala, Ondřej Šorejs, Tomáš Svoboda & Jindřich Fínek. (2018) Axitinib in the second-line treatment of metastatic renal cell carcinoma. Onkologie 12:1, pages 34-37.
Crossref
Crossref
Minsoo Song. (2017) Recent developments in small molecule therapies for renal cell carcinoma. European Journal of Medicinal Chemistry 142, pages 383-392.
Crossref
Crossref
Amparo Sánchez-Gastaldo, Emmanuelle Kempf, Aránzazu González del Alba & Ignacio Duran. (2017) Systemic treatment of renal cell cancer: A comprehensive review. Cancer Treatment Reviews 60, pages 77-89.
Crossref
Crossref
Earle F. Burgess, Stephen B. Riggs, Brian I. Rini & Derek Raghavan. 2016. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
8
.
Takao Kamai, Hideyuki Abe, Kyoko Arai, Satoshi Murakami, Setsu Sakamoto, Yasushi Kaji & Ken-Ichiro Yoshida. (2016) Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report. BMC Cancer 16:1.
Crossref
Crossref
Matthew Scarpelli, Justine Yang Bruce, Lakeesha Carmichael, Jens Eickhoff, Jill Kolesar, Scott Perlman, Robert Jeraj & Glenn Liu. (2016) 18F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen. Cancer Chemotherapy and Pharmacology 78:6, pages 1245-1252.
Crossref
Crossref
Maria Giuseppa Vitale & Giacomo Cartenì. (2016) Clinical management of metastatic kidney cancer: the role of new molecular drugs. Future Oncology 12:1, pages 83-93.
Crossref
Crossref
Justine Yang Bruce, Peter Colin Scully, Lakeesha L. Carmichael, Jens C. Eickhoff, Scott B. Perlman, Jill Marie Kolesar, Jennifer L. Heideman, Robert Jeraj & Glenn Liu. (2015) Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with 18F-3′deoxy-3′fluoro-l-thymidine positron emission tomography/computed tomography. Cancer Chemotherapy and Pharmacology 76:1, pages 187-195.
Crossref
Crossref
Mark ReinwaldTobias BochWolf-Karsten HofmannDieter Buchheidt. (2016) Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomarker Insights 10s3, pages BMI.S22430.
Crossref
Crossref
Amparo Sánchez Gastaldo, Aránzazu González del Alba & Ignacio Durán. 2015. Targeted Therapies for Solid Tumors. Targeted Therapies for Solid Tumors
197
210
.
Luis León, Luis Miguel Antón-Aparicio, Emilio Esteban-González, Martin Lázaro-Quintela & Sergio Vázquez-Éstevez. 2015. Renal Cell Carcinoma. Renal Cell Carcinoma
377
416
.
Xin Ku, Stephanie Heinzlmeir, Dominic Helm, Guillaume Médard & Bernhard Kuster. (2014) New Affinity Probe Targeting VEGF Receptors for Kinase Inhibitor Selectivity Profiling by Chemical Proteomics. Journal of Proteome Research 13:5, pages 2445-2452.
Crossref
Crossref
Andrea Weiss, Judy R. Beijnum, Debora Bonvin, Patrice Jichlinski, Paul J. Dyson, Arjan W. Griffioen & Patrycja Nowak‐Sliwinska. (2014) Low‐dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization. Journal of Cellular and Molecular Medicine 18:3, pages 480-491.
Crossref
Crossref
Jane Mattei, Rodrigo Donalisio da Silva, David Sehrt, Wilson R. Molina & Fernando J. Kim. (2014) Targeted therapy in metastatic renal carcinoma. Cancer Letters 343:2, pages 156-160.
Crossref
Crossref
Ting Zhang, Xiaohua Niu, Lili Liao, Eun-Ah Cho & Haifeng Yang. (2013) The Contributions of HIF-Target Genes to Tumor Growth in RCC. PLoS ONE 8:11, pages e80544.
Crossref
Crossref
George Dranitsaris, Susanne Schmitz & Reuben J. Broom. (2013) Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy. Journal of Cancer Research and Clinical Oncology 139:11, pages 1917-1926.
Crossref
Crossref
Ying Chen, Michael A. Tortorici, May Garrett, Brian Hee, Karen J. Klamerus & Yazdi K. Pithavala. (2013) Clinical Pharmacology of Axitinib. Clinical Pharmacokinetics 52:9, pages 713-725.
Crossref
Crossref
Davide Melisi, Geny Piro, Anna Tamburrino, Carmine Carbone & Giampaolo Tortora. (2013) Rationale and clinical use of multitargeting anticancer agents. Current Opinion in Pharmacology 13:4, pages 536-542.
Crossref
Crossref
Alyssa Fischer, Shenhong Wu, Alan L. Ho & Mario E. Lacouture. (2013) The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Investigational New Drugs 31:3, pages 787-797.
Crossref
Crossref
Mohammed I. El-Gamal, Hanan S. Anbar, Kyung Ho Yoo & Chang-Hyun Oh. (2013) FMS Kinase Inhibitors: Current Status and Future Prospects. Medicinal Research Reviews 33:3, pages 599-636.
Crossref
Crossref
Giovanni Butturini, Marco Inama, Marco Dal Molin, Mirko D’Onofrio, Davide Melisi, Giampaolo Tortora, Federica Pedica & Paola Capelli. 2013. Uncommon Pancreatic Neoplasms. Uncommon Pancreatic Neoplasms
175
188
.
C. Porta, G. Tortora, C. Linassier, K. Papazisis, A. Awada, D. Berthold, J. P. Maroto, T. Powles & M. De Santis. (2011) Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Medical Oncology 29:3, pages 1896-1907.
Crossref
Crossref
Bernard Escudier, Cezary Szczylik, Camillo Porta & Martin Gore. (2012) Treatment selection in metastatic renal cell carcinoma: expert consensus. Nature Reviews Clinical Oncology 9:6, pages 327-337.
Crossref
Crossref
Napoleone Ferrara. 2012. Twenty Years of G-CSF. Twenty Years of G-CSF
423
433
.
Brian I Rini, Bernard Escudier, Piotr Tomczak, Andrey Kaprin, Cezary Szczylik, Thomas E Hutson, M Dror Michaelson, Vera A Gorbunova, Martin E Gore, Igor G Rusakov, Sylvie Negrier, Yen-Chuan Ou, Daniel Castellano, Ho Yeong Lim, Hirotsugu Uemura, Jamal Tarazi, David Cella, Connie Chen, Brad Rosbrook, Sinil Kim & Robert J Motzer. (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. The Lancet 378:9807, pages 1931-1939.
Crossref
Crossref
Thomas E. Hutson, Ronald M. Bukowski, C. Lance Cowey, Robert Figlin, Bernard Escudier & Cora N. Sternberg. (2011) Sequential use of targeted agents in the treatment of renal cell carcinoma. Critical Reviews in Oncology/Hematology 77:1, pages 48-62.
Crossref
Crossref
Doru T. Alexandrescu & Constantin A. Dasanu. (2009) In Reply. Journal of Clinical Oncology 27:3, pages 473-474.
Crossref
Crossref
Jie Ma & David J. Waxman. (2008) Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Molecular Cancer Therapeutics 7:12, pages 3670-3684.
Crossref
Crossref